Next Phase Newsletter

A healthcare-dedicated investment firm founded in 2015 with offices in USA has 4 active investment vehicles that allow them to work with companies across various stages of development including private equity, long/short hedge fund, crossover venture fund, and SPAC.

In terms of early-stage opportunities, the firm allocates a few million dollars as initial investment (at a minimum), amount varying on a deal-by-deal basis, and is capable of investing up to $50M over the company’s lifecycle. The firm is open to North American and European opportunities.

The firm is interested in therapeutics, medical devices, tools, labs/diagnostics, and pharmaceutical services. The firm is opportunistic in terms of subsectors and will consider all things healthcare.

The firm prefers to work with management teams that have entrepreneurial experience. The business must show strong potential, and either be revenue-generating or have visibility to approach positive revenue in the next 12-24 months. The company should be built around strong and distinguishable IP that presents a significant market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical headquartered in China with more than 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.) has their main business covering chemical and biological medicines, pharmaceutical packaging, and trading.

The investment subsidiary of this pharmaceutical has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development.  The firm also invests in funds. The firm’s allocation size is decided case by case.

The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2017, a family office located in USA and registered in the Cayman Islands manages a small angel fund that invests in angel and seed stage, and its typical allocation size is between $100,000 to $250,000. The firm invests in companies based in the United States, especially in the Silicon Valley area, and normally invests four to five companies every year.

The firm is interested in diagnostics and medical devices in general, especially cancer diagnostics. Regarding therapeutics, it is open to the data platforms for therapeutics and Orphan diseases.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A recently formed venture capital firm focuses on the big-data aspect of personalized diagnostics. The firm is seeking early-stage companies raising seed to Series B rounds. The firm has a $200M target fund and seeks to make 15 –20 new investments within the year. The firm seeks to make $2M – $4M initial investments per company, but will make smaller initial seed investments. The firm prefers to be actively involved in their portfolio companies, and therefore prefers companies based near the west coast, though is open to other U.S.-based companies.

The firm is focused on early-detection diagnostics, such as discovering cancer when it is still monogenetic versus heterogeneous and already invaded in other parts of the body or detecting Alzheimer’s 8-10 years before dementia symptoms are present. The firm is interested in point-of-care diagnostics (for influenza A/B/bacterial, etc.) that can diagnose specifically and efficiently. The firm is especially interested in technology with a big-data component, and involved in genomics and personalized medicine to provide the right treatment as early as possible. The firm seeks preclinical to clinical-stage technology, though will also look later-stage depending on the opportunity.

The firm requires a smart management team that is diverse in knowledge, and a company with good IP that may come from a leading institution. The firm will usually seek early-stage companies with less than half a dozen people.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.